Back to top

Image: Bigstock

Veru (VERU) Up on FDA's Fast Track Tag for Breast Cancer Drug

Read MoreHide Full Article

Shares of Veru Inc. (VERU - Free Report) were up 20% after it announced on Monday that the FDA had granted Fast Track designation to the phase III registration study on its breast cancer candidate, enobosarm.

The phase III ARTEST study is investigating enobosarm for the treatment of third-line metastatic androgen receptor positive, estrogen receptor positive, human epidermal growth factor receptor 2 negative (AR+ER+HER2-) breast cancer in patients having experienced previous disease progression on a nonsteroidal AI, fulvestrant, and CDK 4/6 inhibitor therapy, and who have AR% nuclei staining ≥40% in breast cancer tissue. Enrollment is currently ongoing in the study.

The FDA provides a Fast Track designation to help the development and faster review of drugs that treat serious and unmet medical conditions. The designation will also make the candidate eligible for priority review and accelerated approval upon successful development.

Veru’s stock has declined 30.4% in the past year compared with the industry’s decrease of 9.1%.

Zacks Investment ResearchImage Source: Zacks Investment Research

Enobosarm is a selective androgen receptor agonist targeting androgen receptors in AR+ ER+ HER2- metastatic breast cancer indication.

Apart from the ARTEST registration study, enobosarm is also being tested in other studies for treating breast cancer.

A planned phase II study will investigate enobosarm in combination with Veru’s cytoskeleton disruptor, sabizabulin, for treating patients with metastatic triple-negative breast cancer after two systemic chemotherapies.

Also, the planned phase III ENABLAR-2 study is evaluating enobosarm in combination with Eli Lilly’s (LLY - Free Report) Verzenio (abemaciclib) for the treatment of second-line metastatic AR+ER+HER2- breast cancer in patients whose disease progressed following treatment with palbociclib and either a nonsteroidal AI or fulvestrant combination with an AR nuclei staining of ≥40%.

Eli Lilly’s breast cancer drug, Verzenio, is witnessing a solid uptake owing to increased demand. In the first nine months of 2021, the drug generated sales worth $945.8 million, reflecting an increase of 50% year over year. Eli Lilly is also studying Verzenio for other cancer indications.

Please note that fulvestrant is marketed by AstraZeneca (AZN - Free Report) under the trade name Faslodex. It is one of the legacy cancer drugs in the company’s portfolio.

AstraZeneca is facing intense generic competition for Faslodex, which is hurting the drug’s sales. In the first nine months of 2021, Faslodex generated sales worth $329 million, reflecting a decrease of 29% year over year.

If successfully developed and upon potential approval, enobosarm can tap into a market with significant potential and drive revenues for Veru in future quarters.

Zacks Rank & Stock to Consider

Veru currently carries a Zacks Rank #3 (Hold). A top-ranked stock in the biotech sector is AnaptysBio, Inc. (ANAB - Free Report) , which has a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

AnaptysBio’s loss per share estimates have narrowed 0.3% for 2022, over the past 60 days. The stock has rallied 47.4% in the past year.

AnaptysBio’s earnings surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AstraZeneca PLC (AZN) - free report >>

Eli Lilly and Company (LLY) - free report >>

AnaptysBio, Inc. (ANAB) - free report >>

Veru Inc. (VERU) - free report >>